Actinium Pharmaceuticals, a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers, has entered into an agreement with Zevacor Pharma for the clinical production and supply of Iomab-B for the upcoming Phase 3 SIERRA trial. Zevacor will perform the GMP manufacturing, testing, releasing and distribution of Iomab-B for the trial. Iomab-B is a radioimmunotherapy intended to be an induction and conditioning agent prior to a bone marrow transplant for acute myeloid leukemia (AML) patients over the age of 55. Actinium’s Iomab-B has received orphan drug designation from the U.S. FDA and the Phase 3 SIERRA trial is expected to enroll 150 patients.

“We are delighted to have Zevaor as our manufacturing and supply partner for Iomab-b and the Phase 3 SIERRA trial,” said Kaushik Dave, chief executive officer, Actinium. “Zevacor is a leading radiopharmaceutical company and it was apparent to us that they possess the knowledge, experience and capabilities to execute on our behalf, which led us to their selection. We look forward to working with the Zevacor team on the execution of the SIERRA trial.”